Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2024-04-02 00:00:00 ET · period of report 2024-03-30 · accession 0001140361-24-017374 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-04-02 | 2024-03-30 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $10.54 | -366.2K | 3.65M | -9% | -$3.86M |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | — | +729.1K | 4.02M | +22% | — |
| DT | 2024-04-02 | 2024-03-30 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $6.40 | -1.86M | 0 | -100% | -$11.88M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-03-30 | F | D | 366,211 | $10.54 | 3,651,985 | D | — | — | |
| 2 | Common | Common Shares | 2024-03-30 | M | A | 729,081 | — | 4,018,196 | D | — | — | (F2) On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 1,856,163 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 729,081 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). (F3) Includes an award of restricted stock covering Common Shares that is fully vested. |
| 3 | Derivative | Capped Value Appreciation Rights | 2024-03-30 | M | D | 1,856,163 | $6.40 | 0 | D | — · — to 2026-03-31 | 729,081 Common Shares | (F2) On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 1,856,163 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 729,081 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. (F6) This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. (F1) Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). |